The “Cell and Gene Therapy CROs Market, 2018-2030” report has been added to ResearchAndMarkets.com’s offering. The Cell and Gene Therapy CROs Market, 2018-2030′ report features a comprehensive … (본문 전체 12/5/2018 11:58 PM)
Cell therapy is an integral part of immunotherapy that has shown excellent therapeutic ability in several clinical indications. In recent years, studies regarding the use of cells for their therapeutic ability have gained immense popularity in the … (본문 전체 12/5/2018 4:13 PM)
Stoke’s ASO therapy is designed to raise the protein to normal levels. “These data are particularly exciting because this approach could lead to the first disease-modifying treatment for patients with Dravet Syndrome. Stoke is also working on applying … (본문 전체 12/2/2018 8:49 PM)
특히 성공사례집(The Journey to Success, Stem Cell & Gene Therapy)에는 국내 8개 선도기업((메디포스트, 신라젠, 제넥신, 코오롱생명과학, SCM … (본문 전체 11/26/2018 11:13 AM)
특히 성공사례집(The Journey to Success, Stem Cell & Gene Therapy)에는 국내 8개 선도기업((메디포스트, 신라젠, 제넥신, 코오롱생명과학, SCM … (본문 전체 11/26/2018 12:32 PM)
해당 연구 결과가 실린 논문은 Inovio 연구진 및 학계 협력 연구진이 저술했으며 Molecular Therapy 저널에 게재되었다. 두 번째 연구는 Cell Reports 저널에 … (본문 전체 11/27/2018 12:58 PM)
특히 성공사례집(The Journey to Success, Stem Cell & Gene Therapy)에는 국내 8개 선도기업((메디포스트, 신라젠, 제넥신, 코오롱생명과학, SCM … (본문 전체 11/26/2018 2:17 PM)
SAN DIEGO — Checkpoint inhibitors appeared to safely and effectively improve outcomes with CD19-directed chimeric antigen receptor T-cell therapy among children with relapsed B-cell acute lymphoblastic leukemia, according to a study presented at ASH … (본문 전체 12/2/2018 6:57 AM)
Shares of cell therapy developer Fate Therapeutics shot up more than 8% Friday morning to $15.31 after the company announced that the FDA accepted its IND application for a cell therapy it’s developing called FT500 to treat advanced solid tumors. (본문 전체 12/1/2018 1:47 AM)
An international phase-2 trial of a CAR-T cell therapy—to be published on-line Dec. 1 in the New England Journal of Medicine (and presented at the ASH annual meeting in San Diego)—found that … (본문 전체 12/2/2018 8:31 PM)